Evaluation of a Rapid Point-of-Care Multiplex Immunochromatographic Assay for the Diagnosis of Enteric Fever

Shailendra Kumar,a Ariana Nodoushani,b Farhana Khanam,c Alyssa T. DeCruz,a Paul Lambotte,a Robert Scott,a Isaac I. Bogoch,d Krista Vaidya,e Stephen B. Calderwood,b,h,g Taufiqur R. Bhuiyan,c Javan Esfandiari,a Edward T. Ryan,b,f,h Firdausi Qadri,c Jason R. Andrews,i Richelle C. Charlesb,f

aChembio Diagnostic Systems, Inc., Medford, New York, USA
bDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
cInternational Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
dDepartment of Medicine, University of Toronto, Ontario, Canada
eDhulikhel Hospital, Dhulikhel, Nepal
fDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA
gDepartment of Microbiology, Harvard Medical School, Boston, Massachusetts, USA
hDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
iDivision of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA

Jason R. Andrews and Richelle C. Charles contributed equally to this work.

ABSTRACT There is a critical need for an improved rapid diagnostic for enteric fever. We have previously demonstrated that serum IgA responses targeting Salmonella enterica serovar Typhi hemolysin E (HlyE) and lipopolysaccharide (LPS) are able to discriminate patients with acute typhoid from healthy controls in areas where enteric fever is endemic (healthy endemic controls) and from patients with other bacterial infections. We now have data demonstrating that IgA antibody responses against these antigens also work well for identifying patients with acute S. Paratyphi A infection. To develop a test for acute enteric fever detection, we have adapted a point-of-care immunochromatographic dual-path platform technology (DPP), which improves on the traditional lateral flow technology by using separate sample and conjugate paths and a compact, portable reader, resulting in diagnostics with higher sensitivity and multiplexing abilities. In this analysis, we have compared our standard enzyme-linked immunosorbent assay (ELISA) method to the DPP method in detecting acute phase plasma/serum anti-HlyE and anti-LPS IgA antibodies in a cohort of patients with culture-confirmed S. Typhi (n = 30) and Paratyphi A infection (n = 20), healthy endemic controls (n = 25), and febrile endemic controls (n = 25). We found that the DPP measurements highly correlated with ELISA results, and both antigens had an area under the curve (AUC) of 0.98 (sensitivity of 92%, specificity of 94%) with all controls and an AUC of 0.98 (sensitivity of 90%, specificity of 96%) with febrile endemic controls. Our results suggest that the point-of-care DPP Typhoid System has high diagnostic accuracy for the rapid detection of enteric fever and warrants further evaluation.

IMPORTANCE Enteric fever remains a significant global problem, and control programs are significantly limited by the lack of an optimal assay for identifying individuals with acute infection. This is especially critical considering the recently released World Health Organization (WHO) position paper endorsing the role of the typhoid conjugate vaccine in communities where enteric fever is endemic. A reliable diagnostic test is needed to assess and evaluate typhoid intervention strategies and determine which high-burden areas may benefit most from a vaccine intervention. Our
A collaborative team has developed and evaluated a point-of-care serodiagnostic assay based on detection of anti-HlyE and LPS IgA. Our finding of the high diagnostic accuracy of the DPP Typhoid System for the rapid detection of enteric fever has the potential to have significant public health impact by allowing for improved surveillance and for control and prevention programs in areas with limited laboratory capacity.

**KEYWORDS**  
*S.* Paratyphi A, *S.* Typhi, *Salmonella*, diagnostic, enteric fever, paratyphoid, point-of-care, typhoid

**Typhoid and paratyphoid fever**, collectively known as enteric fever, affect more than 14 million people globally and result in around 135,000 deaths each year (1). Enteric fever is prevalent in low-and-middle-income countries (LMICs) that lack access to clean drinking water and improved sanitation, especially in southeast Asia, south Asia, and sub-Saharan Africa (1).

A major unresolved issue in the management, prevention, and control of enteric fever is the absence of a reliable and rapid diagnostic assay. Clinical diagnosis is unreliable (2), and the current reference standard, blood culture, has several limitations, including a low sensitivity of approximately 52 to 70% (3), a several day lag between sample collection and result availability, and requirement of substantial laboratory capacity. Serum-based diagnostics such as the Widal agglutination test, and commercially available assays such as Typhidot and Tubex, while simple and rapid, offer only moderate accuracy in specificity and sensitivity (4). Detecting antibodies secreted from circulating, activated lymphocytes (TPTest) has high sensitivity and specificity for diagnosing enteric fever, but it requires moderately advanced laboratory capacity and requires 18 to 48 h to obtain results (5–7). A rapid diagnostic for enteric fever could improve medical management, reduce overdiagnosis and overuse of antityphoid antimicrobials, which has driven antimicrobial resistance, and improve disease burden estimates and surveillance in areas where enteric fever is endemic, so that informed decisions can be made surrounding vaccine introduction (5). This is especially relevant given the WHO’s prequalification and endorsement of the typhoid-conjugate vaccine (TCV) (8).

There have been several high-throughput immunoscreens of the *Salmonella enterica* serovar Typhi proteome to identify promising antigens that can be used to develop a serodiagnostic assay that allows for accurate identification of patients with enteric fever (9–13). The top candidate antigens have included *S.* Typhi lipopolysaccharide (LPS), hemolysin E (HlyE), cytolethal distending toxin B (CdtB), flagellin, outer membrane protein A (OmpA), pathogenicity island effector proteins SipB and SipC, among others (9–13). All these studies have identified antibody responses to LPS and/or HlyE among the best discriminators of acute typhoid patients from healthy controls from areas where enteric fever is endemic (endemic healthy controls) and other febrile controls (9–13). In a recent analysis, we applied supervising learning methods and two independent cohorts from Bangladesh and Nepal to identify the best antigen and antibody isotype combinations to identify patients with acute typhoid fever. We found that serum IgA responses targeting *S.* Typhi hemolysin E (HlyE) and LPS are able to discriminate patients with acute typhoid illness from healthy endemic area controls as well as from patients with other bacterial infections (14). We now have data demonstrating that IgA antibody responses against these antigens also work well for identifying patients with acute *S.* Paratyphi A infection, which accounts for 10 to 50% of enteric fever infections in areas of Asia (1, 15).

To translate the serologic testing of HlyE and LPS IgA responses into a multiplex rapid test for enteric fever, we have used Chembio’s patented DPP (Dual Path Platform [16, 17]), a point-of-care immunochromatographic technology. The DPP Typhoid System consists of a sample path that distributes a small volume of sample (~10 μl of whole blood, plasma, or serum) onto an antibody detection strip containing a test line for LPS, a test line for HlyE, and a control line (Fig. 1). Results are obtained with the DPP
Micro Reader, a portable, battery-powered instrument using assay-specific algorithms to verify the presence of the control line and displays a numerical intensity value for each test line. The device has been designed to minimize human interpretation error. This multiplex system has the capability of measuring plasma IgA responses to both LPS and HlyE with high sensitivity and specificity, and its results were highly correlated with ELISA results.

RESULTS AND DISCUSSION

Characterization of anti-LPS and HlyE IgA responses. We evaluated plasma and serum IgA responses to LPS and HlyE antigens by ELISA and DPP Typhoid System using previously collected samples from three cohorts of individuals: (i) patients at the acute phase of enteric fever (day of presentation to a health facility), with blood culture-confirmed *S. Typhi* (*n* = 30) or *S. Paratyphi* A (*n* = 20); (ii) healthy controls from Bangladesh, an area where typhoid is endemic (*n* = 25); and (iii) febrile controls from Nepal with other bacteremias (i.e., *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Streptococcus* spp.; *n* = 25).

We found higher IgA immunoreactivity to LPS and HlyE in *S. Typhi* and *S. Paratyphi* A cases by ELISA and DPP compared to healthy controls from areas where enteric fever is endemic (endemic healthy controls) (*P* < 0.0001) and endemic febrile controls (*P* < 0.0001) (Fig. 2 and 3, respectively).

Comparison of DPP Typhoid System measurements to reference ELISA results. The anti-LPS and HlyE IgA ELISA and DPP measurements had a high degree of linear
correlation in both negative and positive serum samples, \( r = 0.86 \) (\( P < 0.0001 \)) and 
\( r = 0.82 \) (\( P < 0.0001 \)), respectively (Fig. 4). To further characterize DPP performance agreement with ELISA, we also performed a Bland-Altman plot of the log-transformed data, which demonstrated strong agreement between the two tests without significant bias (Fig. 5).

**Accuracy of the DPP Typhoid System.** We assessed classification accuracy of the DPP Typhoid System by receiver operating characteristic (ROC) area under the curve (AUC) (Table 1 and Fig. 6). The combined antigens (HlyE and LPS) in the DPP Typhoid System distinguished plasma from enteric fever cases from individuals presenting with other invasive bacteremias with a sensitivity of 90% and specificity of 96% (AUC, 0.98). HlyE alone had an AUC of 0.95 (sensitivity of 90%, specificity of 92%), and LPS alone had an AUC of 0.95 (sensitivity of 90%, specificity of 88%). When including all endemic controls (healthy and febrile), the DPP had an AUC of 0.98 for the combined antigens (sensitivity of 92%, specificity of 94%), AUC of 0.93 for HlyE alone (sensitivity of 90%, specificity of 84%) and AUC of 0.96 for LPS alone (sensitivity of 90%, specificity of 92%).

We also evaluated receiver operating characteristic curves for *S. Typhi* and *S. Paratyphi A* cases, independently, for each antigen (see Table S1 in the supplemental material). Use of the combined antigens (HlyE or LPS) by the DPP Typhoid System could discriminate typhoid fever from endemic febrile controls with a sensitivity of 96% and specificity of 100% (AUC, 1.00), and all endemic controls with a sensitivity of 96% and specificity of 100% (AUC, 1.00). These results were in line with our prior findings of

---

**FIG 3** Characterization of anti-HlyE IgA plasma responses using ELISA (A) and DPP (B). Individual and median anti-HlyE responses with interquartile range for patients at acute phase (day 0) of enteric fever (*S. Typhi* or Paratyphi A), healthy and febrile controls from a typhoid-endemic area (endemic healthy and endemic febrile). Differences between cases and control groups were assessed using the Mann-Whitney test. A \( P \) of \(<0.05\) was considered significant. ***, \( P < 0.0001 \) (red, *S. Typhi*; black, *S. Paratyphi A*).

**FIG 4** Correlation between ELISA and DPP Typhoid System measurements. (A and B) Plot of anti-LPS (A) and anti-HlyE (B) IgA plasma measurements by ELISA versus DPP Typhoid System of acute enteric fever cases (red, *S. Typhi* or *S. Paratyphi A*) and controls (black, endemic healthy and febrile controls). The Pearson correlation coefficient (\( r \)) is shown.
excellent discriminatory values for HlyE and LPS IgA responses in identifying patients with typhoid fever. The discriminatory power of anti-LPS IgA for paratyphoid A fever and controls was not as high as for typhoid fever, but the combined antigens measured by DPP could accurately distinguish samples from patients with paratyphoid fever from samples of endemic febrile controls with a sensitivity of 90% and specificity of 92% (AUC, 0.97) and from all endemic controls with a sensitivity of 90% and specificity of 88% (AUC, 0.97) (Table S1).

**Conclusion.** There is a critical need for a rapid, accurate diagnostic assay for enteric fever. Available rapid serodiagnostics for typhoid fever have moderate sensitivity and specificity (3), and there have been limited evaluations of rapid test diagnostics for paratyphoid fever (4). In this study, we developed and evaluated a rapid assay for the detection of patients with typhoid and paratyphoid fever, the DPP Typhoid System, based on the detection of serum/plasma IgA responses to LPS and HlyE. To evaluate the performance of the assay, we tested samples collected from enteric fever cases and controls by the DPP Typhoid System and by our reference ELISA method (14). The detection of anti-HlyE and LPS IgA in samples by DPP showed excellent agreement with results from ELISA, demonstrated high sensitivity and specificity in identifying patients with culture-confirmed enteric fever, and distinguished those individuals from controls in areas where enteric fever is endemic. These data suggest that the DPP Typhoid System may be a promising tool for diagnosing individuals with enteric fever.

Advantages of this potential point-of-care assay include its ease of handling, rapid turnaround time, minimal sample volume requirement (with potential to use 10 μL of finger prick blood, serum, or plasma), and minimal to no requirement of laboratory capacity or training. In addition, it can identify individuals with either *S. Typhi* or *S. Paratyphi* A infection. Prior serodiagnostic assays for typhoid fever have been based on IgG and/or IgM responses to various *S. Typhi* target antigens (4). These assays have had limited sensitivity and specificity due to the high background seroprevalence of IgG.

**TABLE 1** Receiver operating characteristic area under the curve (AUC) for anti-HlyE and LPS IgA using DPP for distinguishing enteric fever cases (*S. Typhi* or *S. Paratyphi* A) patients from controls.

| Antigen(s) | Febrile controls | All endemic controls |
|------------|------------------|---------------------|
|            | Specificity (%)<sup>a</sup> & Sensitivity (%)<sup>c</sup> | Specificity (%) & Sensitivity (%)<sup>c</sup> |
| HlyE       | 0.95 (0.90–1.00) | 92                   | 89                   | 0.93 (0.88–0.98) | 84 | 84 |
| LPS        | 0.95 (0.90–1.00) | 88                   | 88                   | 0.96 (0.92–1.00) | 92 | 91 |
| Both       | 0.98 (0.9–1.00)  | 96                   | 90                   | 0.98 (0.96–1.00) | 98 | 92 |

<sup>a</sup>Values for both antigens are shown in boldface type.

<sup>b</sup>Specificity at 90% sensitivity.

<sup>c</sup>Sensitivity at 90% specificity.
and the cross-reactivity of IgM in areas where enteric fever is endemic (4). Measurement of IgA in the DPP Typhoid System overcomes some of these limitations due to the relative transience in plasma of antigen-specific IgA compared to IgG antibodies and improved specificity over IgM antibodies (11).

A limitation of our analysis is that the test thus far has been evaluated only with stored plasma and serum samples from a small cohort of adult cases and controls from Asia. Future studies will need to include assessment of assay performance for (i) other sample types (e.g., capillary whole blood from finger stick); (ii) other populations/settings (e.g., Africa, elsewhere in Asia); (iii) different age groups, particularly young children; (iv) different stages of illness (e.g., days of fever prior to presentation), and (v) various alternative febrile illness (e.g., dengue, chikungunya, scrub typhus, and other invasive bacteremias, particularly invasive nontyphoidal Salmonella [iNTS]), to evaluate for cross-reactive antibodies to HlyE and LPS. HlyE is present in human-specific Salmonella serovars, S. Typhi and S. Paratyphi A. Although absent in the primary Salmonella serovars causing iNTS (S. Typhimurium and S. Enteritidis), it can be found in other iNTS (including S. Schwarzengrund, Montevideo, Bredeney) (18–20) as well as several strains of E. coli (21, 22).

We have previously demonstrated that HlyE IgA retained discriminatory value with other non-Salmonella Gram-negative organisms (i.e., E. coli and Klebsiella) (14). Another study of Nigerian children that included 86 S. Typhi and 29 iNTS culture-confirmed cases demonstrated negligible IgA responses to HlyE except for two patients with low immunoreactivity (11). This study did demonstrate some cross-reactivity to S. Typhi LPS in patients with iNTS (IgM > IgG > IgA) (11), which may potentially be due to conserved epitopes in the core lipopolysaccharide and lipid A regions (11). Further studies of DPP will need to be performed to investigate whether IgA responses to our selected antigens (LPS and HlyE) are able to discriminate enteric fever from iNTS.

Despite the limitations of our analysis, the excellent agreement of the DPP Typhoid System with our ELISA method, which has been tested more broadly (14), suggests that the DPP Typhoid System is a promising assay for the rapid detection of enteric fever and warrants further prospective analysis.

MATERIALS AND METHODS

Plasma/serum samples. Samples were obtained from participants with enteric fever on the day of presentation to the International Centre for Diarrheal Disease Research, Dhaka, Bangladesh (icddr,b) Dhaka hospital, Mirpur field site (Dhaka, Bangladesh); or Dhulikhel Hospital, a Kathmandu University Hospital (Kavrepalanchowk), Nepal, with self-reported fever of 3- to 7-day duration without an obvious focus of infection or alternate diagnosis. Bacteremia was confirmed by blood culture using BacT/Alert or Bactec 9050 automated system (BD Diagnostics) with identification of isolates by standard culture and biochemical tests (23, 24). Serum/plasma was also collected from healthy typhoid-endemic and North American controls and from North American patients presenting with an alternative febrile illness (PCR-confirmed influenza or bacteremia with S. aureus, E. coli, or K. pneumoniae). All samples were collected with the approval of the following Research and Ethical Review Committees and/or Institutional
Immunizations and hybridoma development were performed by the Monoclonal Antibody Core facility of the Dana-Farber Cancer Institute, Boston, MA, as previously described (25, 26). Briefly, three mice (BALB/c, C57BL/6, and Swiss-Webster), 4 to 6 weeks old, were obtained from Charles River Laboratories (Wilmington, MA). All animals were acquired and maintained according to the guidelines of the Institutional Animal Care and Use Committee of Harvard Standing Committee. Mice were immunized at three subcutaneous sites and one intraperitoneal site with 50 μg of purified HlyE emulsified with an equal volume of complete Freund’s adjuvant (Sigma Chemical Co., St. Louis, MO). Mice were again boosted at day 14, and sera were collected. The mouse with the highest serum titer to HlyE was boosted again at day 35, and then the spleen and lymph nodes were collected, and cells were processed for fusion with SP 2/0 myeloma cells (ATCC no. CRL8-006, Rockville, MD) at a ratio of 2:1. Positive hybridomas and subclones were selected by indirect ELISA on HlyE and counterscreened with an irrelevant antigen. The sequenced variable regions of the light and heavy chains of selected hybridomas were cloned into pcDNA3.4 vector containing the human IgG1 and IgA1 heavy chain. The resulting plasmids were then transfected into Exp293F cells. Antibodies were purified from the cell culture supernatant by IgA affinity resin and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blotting, and size exclusion chromatography (SEC)-high-performance liquid chromatography (HPLC) (TSKgel G3000SWxl column; Tosho) to confirm molecular weight and purity. Sequencing, cloning, and antibody purification were performed by GenScript (Piscataway, NJ).

**Development of chimeric HlyE MAb s.** Immunizations and hybridoma development were performed by the Monoclonal Antibody Core facility of the Dana-Farber Cancer Institute, Boston, MA, as previously described (25, 26). Briefly, three mice (BALB/c, C57BL/6, and Swiss-Webster), 4 to 6 weeks old, were obtained from Charles River Laboratories (Wilmington, MA). All animals were acquired and maintained according to the guidelines of the Institutional Animal Care and Use Committee of Harvard Standing Committee. Mice were immunized at three subcutaneous sites and one intraperitoneal site with 50 μg of purified HlyE emulsified with an equal volume of complete Freund’s adjuvant (Sigma Chemical Co., St. Louis, MO). Mice were again boosted at day 14, and sera were collected. The mouse with the highest serum titer to HlyE was boosted again at day 35, and then the spleen and lymph nodes were collected, and cells were processed for fusion with SP 2/0 myeloma cells (ATCC no. CRL8-006, Rockville, MD) at a ratio of 2:1. Positive hybridomas and subclones were selected by indirect ELISA on HlyE and counterscreened with an irrelevant antigen. The sequenced variable regions of the light and heavy chains of selected hybridomas were cloned into pcDNA3.4 vector containing the human IgG1 and IgA1 heavy chain. The resulting plasmids were then transfected into Exp293F cells. Antibodies were purified from the cell culture supernatant by IgA affinity resin and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blotting, and size exclusion chromatography (SEC)-high-performance liquid chromatography (HPLC) (TSKgel G3000SWxl column; Tosho) to confirm molecular weight and purity. Sequencing, cloning, and antibody purification were performed by GenScript (Piscataway, NJ).

**DPP Typhoid System.** The DPP Typhoid System employs Chembio’s patented Dual Path Platform (DPP) technology, which consists of a sample path and reagent path that intersect in the analyte detection area in the readout window of the test cassette that is labeled test (1, 2) and control (C) (Fig. 1). It employs an antibody conjugated (anti-human IgA) to colloidal gold dye particles and S. Typhi LPS and HlyE antigens that are bound to the membrane for capture of the antibody, if present in the sample. To initiate the test, a 10-μl specimen is diluted with 5 drops (150 μl) of sample buffer in a sample tube, and 100 μl sample and buffer mixture is applied to the Sample + Buffer well (well 1) of the DPP test cassette. The specimen flows along the sample path membrane and is delivered to the test zone of the reagent strip, where specific LPS and HlyE antigens (test 1 and 2, respectively) and a control (C) (protein A) are immobilized. If the specimen contains anti-LPS anti-HlyE IgA antibodies, they bind instantly to the respective immobilized test antigens (test 1 and 2), while nonspecific antibody binds to the protein A control (C) line. Five minutes after adding the specimen, 6 drops (150 μl) of buffer are added to the Buffer well (well 2). The buffer hydrates and releases the anti-human IgA antibody gold conjugate, which migrates to the test zone and binds to the captured IgA antibodies targeting LPS and/or HlyE in the respective test areas, producing a pink/purple line. The gold conjugate continues to migrate through the membrane, producing a pink/purple line in the control (C) area containing protein A. This procedural control serves to demonstrate that specimen and reagents have been properly applied and have migrated through the device. In the absence of antibodies against LPS or HlyE in the patient’s sample, there are no pink/purple lines produced in the test 1 and 2 area.

Results were read using the DPP Micro Reader (Fig. 1) between 15 and 20 min after the addition of the sample/buffer to well 1. The DPP Micro Reader is a portable, battery-powered instrument that records the reflectance of the test strip surface and uses assay-specific algorithms to interpret the color intensity of the control and test lines. It displays a qualitative result for each analyte (reactive, nonreactive, or invalid) after approximately 3 s based on test-specific cutoff values loaded into the reader. The reader also displays numerical values of test line intensity, allowing for semiquantitative evaluation of antibody levels.

**Statistical analysis.** The distribution of antibody responses in culture-confirmed cases and controls was compared by Wilcoxon rank sum test. The agreement between ELISA and DPP measurements was assessed by Pearson’s correlation and Bland-Altman analysis. The accuracy of ELISA and DPP were assessed by receiver operator characteristic area under the curve (ROC AUC). All analyses were performed using GraphPad Prism 8.2.0 and R software version 3.6.0 (R Project for Statistical Computing; [https://www.R-project.org/](https://www.R-project.org/)).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**TABLE S1, DOCX file, 0.1 MB.**

**ACKNOWLEDGMENTS**

We express our gratitude to the patients for participating in this study and to the field site staff at the icddr,b, Bangladesh.

This work was supported in parts by core grants to the icddr,b. We gratefully...
acknowledge the following donors: the Government of the People’s Republic of Bangladesh, Global Affairs Canada (GAC), Swedish International Development Cooperation Agency (SIDA), and the Department of International Development (UKAid). This work was also supported by grants from the National Institutes of Health (R01AI134814 to R.C.C. and F.Q.; R33AI100023 to R.C.C., E.T.R., and F.Q.), Fogarty International Center (FIC) (Training Grant in Vaccine Development and Public Health [TW005572] to F.K.) and a FIC Global Emerging Leader Award (K43TW010362 to T.R.B.), Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program (72424 to R.C.C.), and the George Rosenkranz Prize to J.R.A.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

1. GBD Typhoid and Paratyphoid Collaborators. 2019. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis 19:369–381. https://doi.org/10.1016/S1473-3099(18)30685-6.

2. Andrews JR, Barkume C, Yu AT, Saha SK, Qamar FN, Garrett D, Luby SP. 2018. Integrating facility-based surveillance with healthcare utilization surveys to estimate enteric fever incidence: methods and challenges. J Infect Dis 218:5268–5276. https://doi.org/10.1093/infdis/jiy494.

3. Mogasale V, Ramani E, Mogasale VV, Park J. 2016. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. Ann Clin Microbiol Antimicrob 15:32. https://doi.org/10.1186/s12941-016-0147-2.

4. Wijeduru L, Mallert S, Parry CM. 2017. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. Cochrane Database Syst Rev 5:CD008892. https://doi.org/10.1002/14651858.CD008892.pub2.

5. Andrews JR, Ryan ET. 2015. Diagnostics for invasive Salmonella infections: current challenges and future directions. Vaccine 33(Suppl 3):C8–C15. https://doi.org/10.1016/j.vaccine.2015.02.030.

6. Islam K, Sayeed MA, Hossen E, Khanam F, Charles RC, Andrews J, Ryan ET, Qadri F. 2016. Comparison of the performance of the TPTest, TubeX, Typhidot and Widal immunodiagnostic assays and blood cultures in detecting patients with typhoid fever in Bangladesh, including using a Bayesian latent class modeling approach. PLoS Negl Trop Dis 10:e0004558. https://doi.org/10.1371/journal.pntd.0004558.

7. Khanam F, Sheikh A, Sayeed MA, Bhuiyan MS, Choudhury FK, Salma U, Perwiz S, Sultana F, Ahmed D, Goswami D, Hossain M, Mamun KZ, Charles RC, Brooks WA, Calderwood SB, Cravioto A, Ryan ET, Qadri F. 2013. Evaluation of a typhoid/paratyphoid diagnostic assay (TPTest) detecting anti-Salmonella IgA in secretions of peripheral blood lymphocytes in patients in Dhaka, Bangladesh. PLoS Negl Trop Dis 7:e2316. https://doi.org/10.1371/journal.pntd.0002316.

8. World Health Organization. 2019. Typhoid vaccines: WHO position paper, March 2018 – Recommendations. Vaccine 37:214–216. https://doi.org/10.1016/j.vaccine.2018.04.022.

9. Charles RC, Liang L, Khanam F, Sayeed MA, Hung C, Leung DT, Baker S, Ludwig A, Harris JB, Larocque RC, Calderwood SB, Qadri F, Felgner PL, Ryan ET. 2014. Immunoproteomic analysis of antibody in lymphocyte supernatant in patients with typhoid fever in Bangladesh. Clin Vaccine Immunol 21:280–285. https://doi.org/10.1128/CVI.00661-13.

10. Charles RC, Sheikh A, Krautis B, Harris JB, Bhuiyan MS, LaRocque RC, Logvinenko T, Sarracino DA, Kudva IT, Eisenstein J, Podolsky MJ, Kalsy A, Brooks WA, Ludwig A, John M, Calderwood SB, Qadri F, Ryan ET. 2010. Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoproteomity proteomics-based technology. Clin Vaccine Immunol 17:1188–1195. https://doi.org/10.1128/CVI.00094-10.

11. Darton TC, Baker S, Randall A, Dongol S, Karkey A, Voysey M, Carter MJ, Jones C, Trapp K, Pabalu P, Cheng Y, Hsu T, Tett A, Walker C, Molina D, Andrews J, Arjyal A, Basnyat B, Pollard AJ, Blohmke CJ. 2017. Identification of novel serodiagnostics signatures of typhoid fever using a Salmonella proteome array. Front Microbiol 8:1794. https://doi.org/10.3389/fmicb.2017.01794.

12. Davies DH, Jain A, Nakajima R, Liang L, Jasinskis A, Supnet M, Felgner PL, Teng A, Pablo J, Molina DM, Obaro SK. 2016. Serodiagnosis of acute typhoid fever in Nigerian pediatric cases by detection of serum IgA and IgG against hemolysin E and lipopolysaccharide. Am J Trop Med Hyg 95:431–439. https://doi.org/10.4269/ajtmh.15-0869.

13. Liang L, Juarez S, Nga TV, Dunstan S, Nakajima-Sasasi R, Davies DH, McSorley S, Baker S, Felgner PL. 2013. Immune profiling with a Salmonella Typhi antigen microarray identifies new diagnostic biomarkers of human typhoid. Sci Rep 3:1043. https://doi.org/10.1038/srep01043.

14. Andrews JR, Khanam F, Rahman N, Hossain M, Bogoch II, Vaidya K, Kelly M, Calderwood SB, Bhuiyan TR, Ryan ET, Qadri F, Charles RC. 2018. Plasma IgA responses against two Salmonella Typhi antigens identify patients with typhoid fever. Clin Infect Dis 68:949–955. https://doi.org/10.1093/cid/cyz578.

15. Arndt MB, Moises EM, Tian M, Forouzanfar MH, Mohdad AH, Meller M, Ochial RI, Watson JL. 2014. Estimating the burden of paratyphoid A in Asia and Africa. PLoS Negl Trop Dis 8:e2925. https://doi.org/10.1371/journal.pntd.0002925.

16. Chembio Diagnostic Systems Inc. March 2007. Dual path immunoassay device. US patent 7189522.

17. Chembio Diagnostic Systems Inc. September 2006. Dual path immunoassay device. International patent WO/2006/099191.

18. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricia L, Hoelzer K, Rodriguez-Rivera LD, Brown S, Bolchacova E, Furtado MR, Wiedmann M. 2011. Genome sequencing reveals diversification of virulence factor content and possible host adaptation in distinct subpopulations of Salmonella enterica. BMC Genomics 12:425. https://doi.org/10.1186/1471-2164-12-425.

19. Fuentes JA, Villagra N, Castillo-Ruiz M, Mora GC. 2008. The Salmonella Typhi hlyE gene plays a role in invasion of cultured epithelial cells and its functional transfer to S. Typhimurium promotes deep organ infection in mice. Res Microbiol 159:279–287. https://doi.org/10.1016/j.resmic.2008.02.006.

20. Suez J, Porwollik S, Dagan A, Marzel A, Schorr YI, Desai PT, Agmon V, McClelland M, Rahav G, Gal-Mar O. 2013. Virulence gene profiling and pathogenicity characterization of non-typhoidal Salmonella accounted for invasive disease in humans. PLoS One 8:e58449. https://doi.org/10.1371/journal.pone.0058449.

21. Ludwig A, von Rhein C, Bauer S, Huttinger C, Goebel W. 2004. Molecular analysis of cytolyxin A (CyaA) in pathogenic Escherichia coli strains. J Bacteriol 186:5311–5320. https://doi.org/10.1128/JB.186.13.5311-5320.2004.

22. Oscarsson J, Westerman M, Lofsdahl S, Olsen B, Palmgren H, Mizuno Y, Wai SN, Uhlin BE. 2002. Characterization of a pore-forming cytotoxin expressed by Salmonella enterica serovars typhi and paratyphi A. Infect Immun 70:5759–5769. https://doi.org/10.1128/IAI.70.12.5759-5769.2002.

23. Talwadekar NN, Vadher PJ, Antani DU, Kale VV, Kamat SA. 1989. Chromic ammonical resistant Salmonella species isolated between 1978 and 1987. J Postgrad Med 35:79–82.

24. Cruickshank R, Duguid JP, Marmion BP, Swain RHA (ed). 1975. The Medical microbiology, 12th ed. Churchill Livingstone, Edinburgh, UK.

25. Kearney JF, Radbruch A, Liesegang B, Rajewsky K. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550.

26. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497. https://doi.org/10.1038/256495a0.